Real-world retrospective study of prostate-specific antigen and safety assessment with darolutamide plus androgen deprivation therapy for metastasis hormone-sensitive prostate cancer

CONCLUSIONS: For treating prostate cancer, DARO with ADT has good early efficacy, demonstrating prompt and substantial control of PSA levels, with a favorable safety profile.PMID:38590967 | PMC:PMC10999023 | DOI:10.21037/tau-24-96

Source: Cancer Control - April 9, 2024 Category: Cancer & Oncology Authors: Jia Liu Shenghan Wang Yong Yang Shuo Wang Davide Campobasso Yu Guang Tan Qiang Gao Lin Yang Yudong Cao Yongpeng Ji Peng Du Bao Zhang Source Type: research